Aktiesnakken — December 2009
-
vi begynder nu........
-
"sorry to announce Genmab has left the building"
-
en stakåndet london analytiker...præsenterer Liza & David......
-
launched in us two weeks. First sales data...med royalty først i 2010!
-
EGFR kan blive registreret i slut 2010
-
Approval i Europe i h1 2010
-
17 studies i Arzerra. Broaden the label og også RA!
-
potential milestones....commercialisation of arzerra
-
nu q&a
-
arzerra i refrac....hvordan er markedet
-
det er analytikernes stinker
-
mellem 80 og 100.000 cll patienter.
-
75% af disse vil være eligble
-
så der vil være 75K patienter US mulige!!!!
-
the market potential is very large under the guidelines!
-
de fleste vil være dækket af medicare
-
safety data gode....
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind